Drug intelligence / Profile preview

PF-06954522

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-06954522 is an oral small molecule agonist of the glucagon-like peptide 1 receptor (GLP-1R), developed by Pfizer using Sosei Heptares’ StaR technology. It is being investigated primarily for the treatment of type 2 diabetes mellitus and obesity. As a GLP-1 receptor agonist, it mimics the action of endogenous GLP-1, enhancing glucose-dependent insulin secretion and suppressing glucagon release, which helps regulate blood sugar levels. The drug is currently in Phase 1 clinical trials for both type 2 diabetes and obesity[1][2][3][4][5].

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on PF-06954522.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06954522.

Explore the full profile